PTEN KO and, to a lesser degree, PIK3CA overexpression mediated resistance to a panel of PI3K inhibitors. (A-N) Proliferation assays implemented 72 hours after exposure to the indicated agents: idelalisib (1 and 10 μM), duvelisib (1 and 10 μM), AZD8186 (1 and 10 μM), AZD8835 (1 and 10 μM), alpelisib (1 and 10 μM) (F), copanlisib (0.01 and 0.1 μM), and capivasertib (1 and 10 μM); the cellular proliferation of the treated cells was normalized to the cellular proliferation of the untreated cells (n = 3); data are represented as means ± SD; ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001; (N) represents the number of biological replicates. CTRL, control.